Physician-led Wharton's jelly MSC & exosome programs for motor neuron support
Stem cell therapy for ALS in Istanbul, Turkey
How our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your neurological records and designs an individualized intrathecal and intravenous regenerative protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Amyotrophic lateral sclerosis (ALS) places relentless biological stress on the upper motor neurons in the cerebral cortex and the lower motor neurons along the brainstem and spinal cord. As the surrounding glial neighborhood becomes chronically inflamed, motor pathways gradually lose the metabolic and trophic support required to transmit clean signals to skeletal muscles, affecting limb strength, posture, speech, swallowing comfort, and everyday physical endurance.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated in ALS for their ability to remodel this hostile neuro-immune microenvironment and nourish surviving motor units. Inside the central nervous system and systemic circulation, WJ-MSCs and nanoscale exosomes work to downregulate destructive pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 while shifting overactive M1 microglia and reactive astrocytes toward a neuroprotective M2 reparative phenotype. Simultaneously, their paracrine secretome and vesicular cargo deliver vital neurotrophic and angiogenic growth factors—including BDNF, GDNF, VEGF, and HGF—alongside regulatory microRNAs that help stabilize axonal transport, support mitochondrial energy production, and protect vulnerable neuromuscular junctions from oxidative and excitotoxic stress.
At our Istanbul clinic led by Uzm. Dr. Cihan Bolat, every ALS program begins with a thorough review of your EMG and nerve conduction studies, ALSFRS-R functional scores, brain and spine imaging, and respiratory vital capacity. By matching intrathecal, intravenous, and intranasal administration routes to your specific onset pattern and clinical stage, our protocol aims to support muscular stamina, bulbar and limb stability, and daily functional resilience alongside your ongoing neurologist-directed care at home.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
ALS involves a multi-layered biological cascade within the motor cortex, spinal cord, and neuromuscular junctions where chronic microglial activation, glutamate excitotoxicity, mitochondrial exhaustion, and loss of neurotrophic factors accelerate motor neuron vulnerability—mechanisms directly targeted by regenerative cellular and exosomal signaling.
What our protocol aims to support
- Calming central & systemic neuroinflammation: Our protocol aims to downregulate pro-inflammatory microglial and systemic immune activity while promoting regulatory T-cell and anti-inflammatory cytokine balance across the neuraxis.
- Delivering paracrine neurotrophic support: WJ-MSCs and exosomes release bioactive signaling molecules and growth factors (BDNF, GDNF, VEGF) aimed at supporting the metabolic health and axonal resilience of surviving motor pathways.
- Supporting functional stamina & daily motor control: By addressing the biological environment around motor units and neuromuscular junctions, treatment aims to support muscular endurance, posture, and functional independence alongside physical therapy.
- Coordinated integration with your home ALS neurologist: Every regenerative protocol is designed to complement—never interrupt—your prescribed disease-modifying medications (such as riluzole or edaravone) and specialist care at home.
- 01
Microglial & astrocyte neuroinflammation
In ALS, resident microglia and astrocytes in the motor cortex and anterior horn of the spinal cord shift into a persistent pro-inflammatory state, releasing TNF-α, IL-1β, and reactive oxygen species that damage neighboring motor neurons. Wharton's jelly MSCs and their exosomes interact directly with these immune cells to promote a shift from neurotoxic M1 microglial activity toward a reparative M2 phenotype. By upregulating anti-inflammatory cytokines and regulatory T-cell pathways, the biologics help quiet glial hostility around surviving motor tracts. Calming this neuro-inflammatory cascade reduces secondary bystander stress on functional motor units.
- 02
Deficient neurotrophic & paracrine signaling
Surviving upper and lower motor neurons in ALS face a progressive shortage of local neurotrophic growth factors required to sustain their long axons and high metabolic demands. WJ-MSCs and WJ-MSC exosomes secrete a rich paracrine profile including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF). When delivered into the cerebrospinal fluid and circulation, these trophic molecules bind to neuronal receptors to support survival pathways and axonal protein transport. Replenishing this trophic reservoir helps stressed motor neurons maintain stronger synaptic communication.
- 03
Oxidative stress & neuromuscular junction strain
Mitochondrial energy deficits and glutamate excitotoxicity impair the delicate distal neuromuscular junctions where lower motor neurons connect with skeletal muscle fibers, leading to fasciculations, fatigue, and progressive weakness. Nanoscale exosomes derived from Wharton's jelly MSCs carry antioxidant enzymes, heat-shock proteins, and regulatory microRNAs that help buffer intracellular oxidative stress and support mitochondrial ATP generation. By improving the metabolic resilience of motor axons and Schwann cells, regenerative signaling helps support neuromuscular transmission stability. This cellular support aims to preserve everyday muscular endurance and motor control.
- 04
Blood-brain & blood-spinal cord barrier alterations
Microvascular endothelial stress along the brain and spinal cord compromises tight junctions, allowing peripheral inflammatory cells and cytokines to infiltrate central motor pathways. Intravenous WJ-MSCs and exosomes release angiogenic and vascular-stabilizing factors such as VEGF and angiopoietins that nourish capillary endothelial cells and support barrier integrity. Improved microvascular perfusion enhances oxygen delivery and metabolic waste clearance across spinal and cortical tissue. Supporting the neurovascular unit creates a healthier foundation for central nervous system stability.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Repairing the Glial & Neuro-Immune Microenvironment
Motor neurons do not exist in isolation; their survival depends heavily on healthy surrounding astrocytes, microglia, and microvascular capillaries. When these support cells become chronically inflamed, they release neurotoxic mediators that accelerate axonal breakdown. Targeting this glial neighborhood with regenerative biologics aims to restore a calmer, trophic-rich sanctuary around surviving motor pathways. By quieting neuro-immune hostility, viable motor units are better able to maintain synaptic signaling and metabolic resilience.
Synergistic Action of WJ-MSCs & Nanoscale Exosomes
Wharton's jelly MSCs act as living biological signaling factories that sense inflammatory cues and respond by secreting anti-inflammatory cytokines (such as IL-10 and TGF-β) and expanding regulatory T-cells. Paired with billions of WJ-MSC-derived exosomes, the protocol delivers concentrated neurotrophic factors (BDNF, GDNF, VEGF) and regenerative microRNAs across cellular barriers. These vesicles are taken up directly by stressed neurons and glial cells to support mitochondrial bioenergetics, calm oxidative stress, and stabilize axonal integrity. Together, cellular and cell-free biologics provide both immediate vesicular signaling and sustained paracrine support.
Individualized Multi-Route Planning in Istanbul
Before any travel is scheduled, Uzm. Dr. Cihan Bolat and our medical team evaluate your onset pattern, ALSFRS-R trajectory, EMG findings, and pulmonary function reports in detail. This diagnostic review determines the exact combination of intrathecal CSF delivery, intravenous systemic infusion, and intranasal exosome support suited to your physiology. Every protocol is calibrated with documented laboratory cell counts and coordinated seamlessly alongside your prescribed ALS medications at home.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intrathecal WJ-MSC Administration
Intrathecal administration delivers Wharton's jelly mesenchymal stem cells directly into the cerebrospinal fluid via a carefully planned lumbar puncture, performed with or without sedation depending on clinical circumstances and patient comfort. By bypassing the blood-brain and blood-spinal cord barriers, the cells circulate within the CSF along the spinal cord and cerebral subarachnoid space. Once in this central compartment, WJ-MSCs release neurotrophic growth factors (BDNF, GDNF, VEGF) and anti-inflammatory cytokines directly adjacent to anterior horn motor neurons and corticospinal tracts. This route is chosen to maximize central paracrine availability and calm microglial neuroinflammation where motor pathways need support most.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC Administration
Intravenous infusion introduces high-viability Wharton's jelly MSCs into the systemic circulation to address the peripheral immune and vascular components of ALS. Circulating MSCs interact with peripheral monocytes, macrophages, and T-lymphocytes, shifting systemic immune signaling away from pro-inflammatory cytokine production and expanding regulatory T-cells (Tregs). In addition, systemic paracrine factors support microvascular endothelial health and nourish peripheral motor nerves and skeletal muscle beds. Combining intravenous infusion with intrathecal delivery provides dual central-and-peripheral immunomodulation.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Intravenous WJ-MSC Exosome Administration
WJ-MSC-derived exosomes are nanoscale extracellular vesicles (30–150 nm) packed with neuroprotective proteins, antioxidant enzymes, and regulatory microRNAs. Because of their microscopic lipid-bilayer structure, exosomes circulate freely through the bloodstream and cross biological barriers to reach stressed neural and neuromuscular tissues. Inside target cells, exosomal cargo helps regulate inflammatory gene expression, support mitochondrial energy metabolism, and protect axonal membranes from oxidative damage. Intravenous exosome administration amplifies the immediate intercellular repair signaling of the stem cell protocol.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 04
Intranasal Exosome Administration
Intranasal administration offers a gentle, non-invasive supplementary route designed to deliver concentrated WJ-MSC exosomes across the upper nasal mucosa along the olfactory and trigeminal nerve pathways. Preclinical and translational studies investigate this nose-to-brain corridor as a direct pathway for extracellular vesicles to reach the brainstem and cerebral cortex without needle intervention. While the exact percentage of intranasally administered exosomes reaching specific human brain regions remains under active clinical study, our physicians frequently incorporate intranasal dosing to complement intrathecal and intravenous routes. It provides comfortable, repeatable trophic signaling aimed at cranial and central neural networks.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
ALSFRS-R Functional Trajectory
Tracking limb mobility, fine motor hand tasks, and daily self-care scores over time as neurotrophic and anti-inflammatory signaling supports surviving motor units. Our team follows these functional milestones alongside your home neurologist to evaluate stability and daily independence.
- 02
Respiratory & Postural Stamina
Monitoring forced or slow vital capacity (FVC/SVC), trunk stability, and daytime energy levels. By calming systemic and spinal neuroinflammation, the protocol aims to help patients sustain better physical endurance and breathing comfort during daily routines.
- 03
Limb Strength & Neuromuscular Control
Assessing muscle strength, fasciculation frequency, and gait steadiness in partnership with your physical rehabilitation program. Paracrine support for motor axons and neuromuscular junctions aims to help muscles respond more smoothly to rehabilitation exercises.
- 04
Bulbar Comfort & Speech Clarity
Evaluating speaking endurance, vocal projection, and swallowing ease for patients with bulbar involvement. Targeted central and intranasal trophic signaling aims to support the cranial motor nuclei that coordinate speech and swallowing.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
How our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your neurological records and designs an individualized intrathecal and intravenous regenerative protocol.
Medical history & reports we request
- Neurologist-confirmed diagnosis, onset pattern, and clinical timeline
- Recent ALSFRS-R scores and pulmonary function reports
- EMG, nerve conduction, and brain/spine MRI documentation
- Current medication list, coagulation status, and travel readiness
- Individualized review by Uzm. Dr. Cihan Bolat to determine route and dosing suitability
Clinical suitability & protocol checks
- You should continue all neurologist-prescribed ALS medications and supportive routines before, during, and after your visit to Istanbul.
- Our medical team reviews your respiratory capacity, swallowing comfort, and coagulation labs in advance to ensure safe travel and intrathecal procedure readiness.
- Every patient receives a clear multi-day treatment schedule in Istanbul along with structured remote follow-up after returning home.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- You should continue all neurologist-prescribed ALS medications and supportive routines before, during, and after your visit to Istanbul.
- Our medical team reviews your respiratory capacity, swallowing comfort, and coagulation labs in advance to ensure safe travel and intrathecal procedure readiness.
- Every patient receives a clear multi-day treatment schedule in Istanbul along with structured remote follow-up after returning home.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 NurOwn phase 3 trial
Open study- Product
- Mesenchymal stromal cells induced to secrete neurotrophic factors
- Route
- Three intrathecal administrations
- Study design
- Randomized, double-blind, placebo-controlled phase 3 study
- Finding
- The overall population did not show a statistically significant benefit on the primary responder endpoint or the key ALSFRS-R secondary endpoint, while CSF biomarker shifts confirmed biological activity.
- Limitation
- Post hoc subgroup signals in less-advanced disease are hypothesis-generating and highlight the importance of individualized baseline assessment and realistic clinical expectations.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.